Difference between revisions of "IPH-2101"
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapeutic" to "") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
||
| Line 17: | Line 17: | ||
[[Category:Immunotherapeutic]] | [[Category:Immunotherapeutic]] | ||
| − | + | ||
[[Category:Anti-KIR antibodies]] | [[Category:Anti-KIR antibodies]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 19:48, 27 February 2020
General information
Class/mechanism: Human monoclonal antibody that blocks the interaction of KIR inhibitory receptors on NK (natural killer) cells with their ligands. It is hypothesized that by blocking these inhibitory signals, there will be enhanced activation of NK cells and tumor cell destruction.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.